Batm Advanced Communicat... Share Discussion Threads

[kooba] 06/6/2022 17:24

Grifting Scum.

[kooba] 06/6/2022 17:01

Really not at all as it read as all posts were specifically related to the nothing update on ADOR from Milken junket. Then you go on about not understanding start ups and how revenues build now..it was all about another company. Fair dos on jobbing backwards.

[fse] 06/6/2022 16:33

I was referring to BATM medical .....Adaltis and Ador are at the same locale. If you open Adaltis you will see Ador referenced and ditto the other way around.

[kooba] 06/6/2022 16:00

'Remember they already have rolled out and are selling diagnostic solutions that are advanced and competitive'So this is...?

[fse] 06/6/2022 15:55

Ador and Adaltis are both at the same locale and are very much linked.
Thanks paulisi for posting the above.
Maybe we can have peace on that score at least.

[paulisi] 06/6/2022 15:31

The answer regarding ADOR according to the last results suggests no revenues yetAdor Diagnostics ("Ador"), the Group's associate company, is primarily focused on developing the NATlab molecular biology solution that provides rapid sample-to-answer diagnosis of bacterial, viral or fungal infections using DNA or RNA sampling.During the year, Ador progressed the development of its innovative diagnostics technology that uses the rolling circle amplification ("RCA") method. The RCA method offers a number of advantages over the more prevalent PCR method. This includes allowing for the multiplexing of a far higher number of pathogens, and enabling test results to be provided in a significantly shorter timeframe and with greater accuracy. During the year, clinical trials were successfully completed of the meningitis panel that Ador has developed based on the RCA method. The Group expects Ador to commence sales of RCA-based testing kits to laboratories during the current year. Work also continued on incorporating the RCA method into the NATlab system, which is primarily designed for use at point-of-care rather than laboratories. The Group expects Ador to commence sales of the RCA-based NATlab instruments and reagents to point-of-care settings next year.Ador, alongside the Group's Adaltis subsidiary, also received the backing of the Stop TB Partnership, an international alliance comprising governmental and non-governmental organisations, for a new method that the Group has developed (in cooperation with a leading university in Italy and the University of Heidelberg) for the rapid and comprehensive diagnosis of tuberculosis using the RCA process. The testing and validation of products developed under this programme is taking place, and the Group expects commercial-scale testing to start next year, which is being part-funded under a programme of the Stop TB Partnership.Post year end, as announced on 31 January 2022, the Group and its partners invested an additional $10m into Ador, of which the Group contributed $4m (giving the Group a shareholding of 37.2%). The additional investment will be used to prepare Ador for the pre-production stage, register additional patents (mainly in the US), progress development of more disease panels and certifications, and increase the cooperation with international bodies, including the World Health Organisation.

[kooba] 06/6/2022 15:21

FSE as to 'You also do not seem to appreciate that it's one thing to develop and prove a concept and another to manufacture and finally to market it.'I actually do it was you who said they are selling kit..I merely asked where and how much. If you are now saying it's to early to be selling commercially..your comment does not add up.Stand it up or try not to mislead.

[kooba] 06/6/2022 15:07

Your comments on out of their minds are very funny..biggest criticism of 'in house' funding is that they over value investments to make their fund performance look better ..works in the short term . Ask Allied Minds and Woodford how it plays out longer term...you try to belittle but look increasing ignorant and desperate. Shame really.

[kooba] 06/6/2022 15:03

I thought my comments very straightforward . Your comments on funding are simplistic and yes I do have experience in seed capital thanks son. I asked about the revenues you are referring to ..straight answer might help.Problem is many put stuff up here that doesn't stand up , when challenge instead of any supporting evidence it's just ..oh you don't understand the businesses. Well as it goes I do have the ability to read a BATM update on associate and see it doesn't make sense relative to your posting ..hence the query , if you can substantiate fair enough will just accept it's some sort of guess based on nothing.

[fse] 06/6/2022 14:42

kooba... do you have any experience with seed capital investments and incremental additional financing.
Unless additional funding is achieved by public offer or issuing more shares its pretty difficult to come up with a valuation.
When financing is achieved from existing partners or "in house" you can be pretty sure that the levels are at an attractive rate.
Otherwise the investors /partners are highly unlikely to commit further funds at a "higher" multiple unless they are out of their minds.
You also do not seem to appreciate that it's one thing to develop and prove a concept and another to manufacture and finally to market it.
As far as your other conjecture I would suggest reading over the published results.
If you cant see a change then I honestly don't know what to add.

[kooba] 06/6/2022 14:10

What are they selling already..there is little information publicly available from ADOR.Your comment'Remember they already have rolled out and are selling diagnostic solutions that are advanced and competitive.'The update from Batm in Jan '22 around additional funding said'This investment will enable us to prepare Ador for the pre-production stage and move it towards becoming a commercial clinical solution.'Doesn't sound that ADOR has existing revenues. Perhaps you can clarify. In terms of valuation , i think we established the whole company was valued around $70m post funding. Knowing revenues would help in valuation..on available information though and on normal basis of valuing private company interests it will still be valued at last fund raise unless there is a material basis change in the business to prompt an external revaluation. I can't see such a change yet.

[fse] 02/6/2022 20:45

Here is a link to Ador Nat Lab reader. This video was released 18months ago.
It's well worth watching as it demonstrates how far along Ador diagnostics is in setting a new standard for diagnostics.



As mentioned above the new platform will eventually replace what is already a highly advanced system thats being used now.
The markets are well behind the 8 ball on all of this IMO

[fse] 31/5/2022 15:14

It sounds as if everything is very much on course with this new age RCA diagnostics platform. Remember they already have rolled out and are selling diagnostic solutions that are advanced and competitive.
This is a highly significant "addition"
A few out takes FWIW.
The conference feed back exceeded their expectations and they have added US interest to the mix. Trials are not just planned they are underway in Europe and the US.
This is all further along than I thought.
RCA is not an entirely new concept and has been previously pointed out the US spent a considerable amount of funds trying to get it to work and did not succeed.
Big news is here is that they have managed to get it to work and are at the stage of development for applicable use.

We all wanted an update from the Milken conference and this interview was specific to that. I suppose you can read what you want into it.
The company have been approached by large players to take this forwards and I get the distinct impression we are down to a short list and that is likely part of the expected news flow we will receive this year.
Maybe it would be better conjecture to figure out what BATM stake in ADOR is now worth.
As far as getting approval its not a new drug or an unproven methodology.
Its not going to get held up for years of impact study before being released.

[kooba] 31/5/2022 11:16

He does tend to talk of their affiliated companies like they are 100% owned subsidiaries not minority holdings! Anyway nothing much new but confirms novel technology addressing a massive field and hopefully beneficial for mankind on speed of accurate diagnostic testing..does sound early days for orders as the kit has to be tested and validated in the various approval processes internationally which can be quite exhaustive . The comment on news flow could be a collaboration with major player or further strategic investment in ADOR or accelerated approval process designation due to the potential benefit of early introduction of such speedy accurate diagnostics.

[car1pet] 31/5/2022 11:05

Another POC!!!

[paulisi] 31/5/2022 10:57

Not much to go on from that interview other than we are at proof of concept stage and revenue next year if approved.Strange comment at the end ref lack of news. Something is going on behind the scenes...

[echoridge] 31/5/2022 09:22

HA. Very important proof of life!

[sev22] 31/5/2022 08:55

BATM’s CEO discusses its new rapid system to identify pathogens (31st May 2022):

[oakville] 31/5/2022 08:28

Well it can't get into 2nd gear at the moment. I keep placing buys at around 40p and keep getting them. !

[kooba] 30/5/2022 19:24

I was commenting on someone else's post as it goes."Perhaps they've had a massive order and have forestalled share purchases until they're sure the capital can't be used for another, more profitable purpose."Suggesting they have a massive order..if BATM are not in constant talks to market their products then i would be very surprised..if a contract is a possibility or even a probability a share buyback would not need to be withdrawn until it was deemed restricted..that would normally be when they 'know' something will be signed..this situation would not go on for 2 months in my experience.Still a mystery...no more no less.

[pockstones] 30/5/2022 19:20

Shifty the rat asked sensible questions which the company management has not responded to but to which the company share price has
Follow the money not the the verbiage surely